SEC Form 4 · accession 0001140361-18-031810
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean A. McCarthy
Officer — President and CEO · Director
Period of report
Jul 3, 2018
Accepted (ET)
Jul 6, 2018 · 6:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 3, 2018 | M | 2,028 | $1.5749 | A | 84,091 | D | |
| Common StockF2 | Jul 3, 2018 | S | 2,028 | $25.089 | D | 82,063 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.5749 | Jul 3, 2018 | M | 2,028 | D | — | Feb 8, 2025 | Common Stock | 2,028 | 160,146 | D |
Explanation of responses
- F1The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades in prices ranging from $25.00 to $25.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3This option vests in 48 substantially equal monthly installments starting on the last day of January 2015.